Laurus Labs Limited (NSE: LAURUSLABS)

Market Cap	259.52B
Revenue (ttm)	50.54B
Net Income (ttm)	1.48B
Shares Out	539.16M
EPS (ttm)	2.74
PE Ratio	175.89
Forward PE	70.48
Dividend	0.80 (0.17%)
Ex-Dividend Date	May 8, 2024

Volume	2,126,731
Open	491.70
Previous Close	489.00
Day's Range	479.00 - 493.50
52-Week Range	349.40 - 501.30
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 18, 2024

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 6,007
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LAURUSLABS

Financial Performance

In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.